
-
GENFIT NasdaqGS:GNFT Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.
Location: Parc Eurasanté, Loos, 59120, France | Website: https://www.genfit.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
198.7M
Cash
81.79M
Avg Qtr Burn
N/A
Short % of Float
0.12%
Insider Ownership
0.00%
Institutional Own.
0.52%
Qtr Updated
12/31/24
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Iqirvo® (elafibranor) Details Primary biliary cholangitis, Liver disease | Approved Quarterly sales | |
VS-01 Details Acute-on-Chronic liver failure, Liver disease | Phase 2 Data readout | |
Nitazoxanide (NTZ) Details Non-alcoholic steatohepatitis , Acute-on-Chronic liver failure, Liver disease | Phase 2 Initiation | |
GNS561 Details Liver disease, Cholangiocarcinoma | Phase 1b Data readout | |
Iqirvo® (elafibranor) Details Non-alcoholic steatohepatitis | Failed Discontinued |